it is estimated that over 40 million adults in the united states have elevated triglyceride levels > 200mg/dl and approximately 4.0 million people in the united states have severely high ( tg ³ 500mg/dl ) triglyceride levels , commonly known as very high triglyceride levels . according to the american heart association scientific statement on triglycerides and cardiovascular disease ( 2011 ) , 54 triglycerides also provide important information as a marker associated with the risk for heart disease and stroke , especially when an individual also has low high-density lipoprotein , or hdl-c ( often referred to as good cholesterol ) , and elevated levels of ldl-c ( often referred to as bad cholesterol ) . guidelines for the management of very high triglyceride levels suggest that reducing triglyceride levels is the primary goal in patients to reduce the risk of acute pancreatitis . the effect of vascepa on cardiovascular mortality and morbidity , or the risk for pancreatitis , in patients with hypertriglyceridemia has not been determined . the potential efficacy and safety of vascepa was studied in two phase 3 clinical trials , the marine trial and the anchor trial . at a daily dose of 4 grams of vascepa , the dose at which vascepa is fda-approved , these trials showed favorable clinical results in their respective patient populations in reducing triglyceride levels without increasing ldl-c levels in the marine trial and with a statistically significant decrease in ldl-c levels in the anchor trial . these trials also showed favorable results , particularly with the 4-gram dose of vascepa , in other important lipid and inflammation biomarkers , including apolipoprotein b ( apo b ) , non-high-density lipoprotein cholesterol ( non-hdl-c ) , total-cholesterol ( tc ) , very low-density lipoprotein cholesterol , ( vldl-c ) , lipoprotein-associated phospholipase a2 ( lp-pla2 ) , and high sensitivity c-reactive protein ( hs-crp ) . in these trials , the most commonly reported adverse reaction ( incidence > 2 % and greater than placebo ) in vascepa treated patients was arthralgia ( joint pain ) ( 2.3 % for vascepa vs. 1.0 % for placebo ) . commercialization strategy vascepa became commercially available in the united states by prescription in january 2013 when we commenced sales and shipments to our network of u.s.-based wholesalers . on january 28 , 2013 , we commenced our full commercial launch of vascepa in the united states for use in the marine indication . in preparation for our commercial launch , we recently hired and trained a direct sales force of approximately 275 sales representatives . we also employ various marketing and medical affairs personnel to support our commercialization of vascepa . our clinical and commercial supply is provided to us under agreements with various third-party suppliers . as of the date of this annual report , we have announced that 18 patent applications in the united states have been either issued or allowed and more than 30 additional patent applications are pending in the united states . we are also pursuing patent applications related to vascepa in multiple jurisdictions outside the united states . these patent applications are part of our strategy to protect the commercial potential of vascepa , which generally includes obtaining and maintaining intellectual property rights , maintaining trade secrets , seeking regulatory exclusivity and taking advantage of manufacturing barriers to entry . we believe that our sales and marketing team is well positioned to support the commercialization of vascepa for the marine indication and that a larger sales effort will be required to best support the commercialization of vascepa for the anchor indication , assuming fda approval of the anchor indication . to support the continued commercialization of vascepa , we intend to consider strategic opportunities with larger pharmaceutical companies . from time to time we have held discussions with larger pharmaceutical companies on potential collaborations and other strategic opportunities , and we intend to continue having discussions regarding such opportunities in the future . these strategic opportunities may include licensing or similar transactions , joint ventures , partnerships , strategic alliances , business associations , or a sale of the company . however , we can not estimate the timing of any such potential strategic transaction , and no assurance can be given that we will enter into any such strategic transaction . until such time when we enter into such a strategic transaction , if ever , we plan to continue to execute on our plans to market and sell vascepa on our own . the u.s. market is currently the primary focus for vascepa . opportunities to market and sell vascepa outside of the united states are also under evaluation . prior to commencing our u.s. commercial launch of vascepa in january 2013 , we had no revenue from vascepa . as of the date of this annual report , we do not believe that we can provide a reasonably accurate forecast of vascepa revenues and we provide no guidance regarding anticipated levels of vascepa revenues . 55 during 2012 , we purchased approximately $ 32 million of vascepa api of which $ 21.3 million was capitalized to inventory as of december 31 , 2012 and the balance of which was included as a component of research and development expense either because it was received prior to fda approval of vascepa for the marine indication or because it was used in conjunction with the reduce-it study . the majority of this supply was purchased in the second half of 2012. we anticipate continuing to make substantial purchases of supply during 2013 and beyond . story_separator_special_tag the decrease in research and development expense was primarily due to decreased costs in 2011 for our vascepa cardiovascular program , primarily costs associated with the marine and anchor trials , our two phase 3 clinical trials , the top-line results of which were reported in december 2010 and april 2011 , respectively . the decrease in costs for these trials in 2011 versus 2010 were partially offset by increased clinical costs for the reduce-it cardiovascular outcomes study , which was initiated in the second half of 2011 , and costs associated with submitting our nda in september 2011 for vascepa . ( 2 ) non-cash stock based compensation expense included within research and development was $ 1.5 million for the years ended december 31 , 2011 and 2010 , respectively . general and administrative expense . general and administrative expense for the year ended december 31 , 2011 was $ 22.6 million , versus $ 17.1 million in the prior year , an increase of $ 5.5 million , or 32.2 % . general and administrative expenses for the years ended december 31 , 2011 and 2010 are summarized in the table below : replace_table_token_9_th ( 1 ) general and administrative expense , excluding restructuring , severance and non-cash compensation charges for stock compensation and warrants , for the year ended december 31 , 2011 was $ 14.8 million , versus $ 7.2 million in the prior year , an increase of $ 7.6 million , or 105.6 % . the increase was primarily due to higher staffing levels in 2011 , increased overhead costs for increased office space and higher costs in 2011 for marketing studies and other pre-commercial activities . ( 2 ) non-cash warrant related compensation ( income ) expense for the year ended december 31 , 2011 was $ 0.1 million of income , versus $ 5.7 million of expense in the prior year , a change of $ 5.8 million . warrant related compensation income for the period ended december 31 , 2011 reflects non-cash income for the change in fair value of the warrant derivative liability associated with warrants issued in october 2009 to three former officers of amarin , net of warrants exercised . the income in 2011 was due primarily to the decrease in the fair value of these warrants , the decrease in the fair value of the warrants is due primarily to a decrease in our stock price between december 31 , 2010 and december 31 , 2011 . ( 3 ) non-cash stock based compensation expense for the year ended december 31 , 2011 was $ 7.8 million , versus $ 3.7 million in the prior year period , an increase of $ 4.1 million due primarily to an increase in option awards granted in late 2010 and during the year ended december 31 , 2011 to attract and retain qualified employees . 60 ( 4 ) restructuring , severance and lease exit costs for the year ended december 31 , 2010 represented costs for severance , office consolidation and the relocation of certain operations to our u.s. offices . ( loss ) gain on change in fair value of derivative liabilities . ( loss ) gain on change in fair value of derivative liability for the year ended december 31 , 2011 was expense of $ 22.7 million versus $ 205.2 million in the prior year period . ( loss ) gain on change in fair value of derivative liability is primarily related to the change in fair value of warrants issued in conjunction with the october 2009 private placement . in october 2009 we issued 36.1 million warrants at an exercise price of $ 1.50 and recorded a $ 48.3 million warrant derivative liability , representing the fair value of the warrants issued . as these warrants have been classified as a derivative liability , they are revalued at each reporting period , with changes in fair value recognized in the statement of operations . the fair value of the warrant derivative liability at december 31 , 2010 was $ 230.1 million and we recognized a $ 205.2 million loss on change in fair value of derivative liability for the period ended december 31 , 2010 for these warrants . the fair value of the warrant derivative liability at december 31 , 2011 was $ 123.1 million and we recognized a $ 22.7 million loss on change in fair value of derivative liability for the period ended december 31 , 2011. the decrease in the warrant derivative liability value was due primarily to the exercises of warrants . upon exercise , the fair value of warrants exercised is remeasured and reclassified from warrant liability to additional paid-in-capital . see further discussion of the warrant derivative liability in note 2 and note 7 of the notes to the consolidated financial statements . interest income ( expense ) , net . interest income includes interest earned on cash balances . interest expense for the year ended december 31 , 2011 was $ 0.001 million versus $ 0.02 million in the prior year . other ( expense ) income , net . other ( expense ) income primarily includes gains and losses on foreign exchange transactions . other ( expense ) income for the year ended december 31 , 2011 was a net expense of $ 0.01 million versus income of $ 0.13 million in the prior year . ( provision for ) benefit from income taxes . provision for the year ending december 31 , 2011 was a $ 2.5 million provision versus a $ 0.5 million benefit in the prior year . the current provision relates entirely to the united states operations . we are profitable in the united states as a result of intercompany transactions between our united states subsidiary and our other companies . the increase in the 2011 provision for income taxes primarily relates to the exercise of stock options of which the excess

liquidity and capital resources our sources of liquidity as of december 31 , 2012 include cash and cash equivalents of $ 260.2 million . our projected uses of cash include commercialization of vascepa for the marine indication , preparations for commercialization of vascepa for the anchor indication , the continued funding of the reduce-it cardiovascular outcomes study , working capital and other general corporate activities . our cash flows from operating , investing and financing activities , as reflected in the consolidated statements of cash flows , are summarized in the following table ( in millions ) : replace_table_token_10_th on december 6 , 2012 the company entered into an agreement with biopharma secured debt fund ii holdings cayman lp ( biopharma ) . under this agreement , the company granted to biopharma a security interest in future receivables and all related rights to vascepa , in exchange for $ 100 million received at the closing of the agreement which closing occurred in december 2012. the company has agreed to repay 61 biopharma up to $ 150 million of future revenue and receivables . the first repayment under the agreement is a repayment of $ 2.5 million of interest due to biopharma in november 2013 , subject to the limitation described below . additional quarterly repayments are due thereafter in accordance with the following schedule : $ 2.5 million of interest in the first quarter of 2014 ; $ 8.0 million per quarter in each of the next four quarters , $ 10.0 million per quarter in each of the next four quarters , $ 15.0 million per quarter in each of the next four quarters and a final payment of $ 13.0 million due in may 2017. the quarterly repayments through the third quarter of september 2014 represent interest only . quarterly payments do not begin to reduce the principal balance until the fourth quarter of 2014. these quarterly payments are subject to a quarterly threshold amount whereby , if a calculated threshold , based on quarterly vascepa revenues , is not achieved , the quarterly payment payable in that quarter can at our election be reduced and with the reduction carried forward without interest for payment in a future period .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources our sources of liquidity as of december 31 , 2012 include cash and cash equivalents of $ 260.2 million . our projected uses of cash include commercialization of vascepa for the marine indication , preparations for commercialization of vascepa for the anchor indication , the continued funding of the reduce-it cardiovascular outcomes study , working capital and other general corporate activities . our cash flows from operating , investing and financing activities , as reflected in the consolidated statements of cash flows , are summarized in the following table ( in millions ) : replace_table_token_10_th on december 6 , 2012 the company entered into an agreement with biopharma secured debt fund ii holdings cayman lp ( biopharma ) . under this agreement , the company granted to biopharma a security interest in future receivables and all related rights to vascepa , in exchange for $ 100 million received at the closing of the agreement which closing occurred in december 2012. the company has agreed to repay 61 biopharma up to $ 150 million of future revenue and receivables . the first repayment under the agreement is a repayment of $ 2.5 million of interest due to biopharma in november 2013 , subject to the limitation described below . additional quarterly repayments are due thereafter in accordance with the following schedule : $ 2.5 million of interest in the first quarter of 2014 ; $ 8.0 million per quarter in each of the next four quarters , $ 10.0 million per quarter in each of the next four quarters , $ 15.0 million per quarter in each of the next four quarters and a final payment of $ 13.0 million due in may 2017. the quarterly repayments through the third quarter of september 2014 represent interest only . quarterly payments do not begin to reduce the principal balance until the fourth quarter of 2014. these quarterly payments are subject to a quarterly threshold amount whereby , if a calculated threshold , based on quarterly vascepa revenues , is not achieved , the quarterly payment payable in that quarter can at our election be reduced and with the reduction carried forward without interest for payment in a future period .
```    
 Suspicious Activity Report : it is estimated that over 40 million adults in the united states have elevated triglyceride levels > 200mg/dl and approximately 4.0 million people in the united states have severely high ( tg ³ 500mg/dl ) triglyceride levels , commonly known as very high triglyceride levels . according to the american heart association scientific statement on triglycerides and cardiovascular disease ( 2011 ) , 54 triglycerides also provide important information as a marker associated with the risk for heart disease and stroke , especially when an individual also has low high-density lipoprotein , or hdl-c ( often referred to as good cholesterol ) , and elevated levels of ldl-c ( often referred to as bad cholesterol ) . guidelines for the management of very high triglyceride levels suggest that reducing triglyceride levels is the primary goal in patients to reduce the risk of acute pancreatitis . the effect of vascepa on cardiovascular mortality and morbidity , or the risk for pancreatitis , in patients with hypertriglyceridemia has not been determined . the potential efficacy and safety of vascepa was studied in two phase 3 clinical trials , the marine trial and the anchor trial . at a daily dose of 4 grams of vascepa , the dose at which vascepa is fda-approved , these trials showed favorable clinical results in their respective patient populations in reducing triglyceride levels without increasing ldl-c levels in the marine trial and with a statistically significant decrease in ldl-c levels in the anchor trial . these trials also showed favorable results , particularly with the 4-gram dose of vascepa , in other important lipid and inflammation biomarkers , including apolipoprotein b ( apo b ) , non-high-density lipoprotein cholesterol ( non-hdl-c ) , total-cholesterol ( tc ) , very low-density lipoprotein cholesterol , ( vldl-c ) , lipoprotein-associated phospholipase a2 ( lp-pla2 ) , and high sensitivity c-reactive protein ( hs-crp ) . in these trials , the most commonly reported adverse reaction ( incidence > 2 % and greater than placebo ) in vascepa treated patients was arthralgia ( joint pain ) ( 2.3 % for vascepa vs. 1.0 % for placebo ) . commercialization strategy vascepa became commercially available in the united states by prescription in january 2013 when we commenced sales and shipments to our network of u.s.-based wholesalers . on january 28 , 2013 , we commenced our full commercial launch of vascepa in the united states for use in the marine indication . in preparation for our commercial launch , we recently hired and trained a direct sales force of approximately 275 sales representatives . we also employ various marketing and medical affairs personnel to support our commercialization of vascepa . our clinical and commercial supply is provided to us under agreements with various third-party suppliers . as of the date of this annual report , we have announced that 18 patent applications in the united states have been either issued or allowed and more than 30 additional patent applications are pending in the united states . we are also pursuing patent applications related to vascepa in multiple jurisdictions outside the united states . these patent applications are part of our strategy to protect the commercial potential of vascepa , which generally includes obtaining and maintaining intellectual property rights , maintaining trade secrets , seeking regulatory exclusivity and taking advantage of manufacturing barriers to entry . we believe that our sales and marketing team is well positioned to support the commercialization of vascepa for the marine indication and that a larger sales effort will be required to best support the commercialization of vascepa for the anchor indication , assuming fda approval of the anchor indication . to support the continued commercialization of vascepa , we intend to consider strategic opportunities with larger pharmaceutical companies . from time to time we have held discussions with larger pharmaceutical companies on potential collaborations and other strategic opportunities , and we intend to continue having discussions regarding such opportunities in the future . these strategic opportunities may include licensing or similar transactions , joint ventures , partnerships , strategic alliances , business associations , or a sale of the company . however , we can not estimate the timing of any such potential strategic transaction , and no assurance can be given that we will enter into any such strategic transaction . until such time when we enter into such a strategic transaction , if ever , we plan to continue to execute on our plans to market and sell vascepa on our own . the u.s. market is currently the primary focus for vascepa . opportunities to market and sell vascepa outside of the united states are also under evaluation . prior to commencing our u.s. commercial launch of vascepa in january 2013 , we had no revenue from vascepa . as of the date of this annual report , we do not believe that we can provide a reasonably accurate forecast of vascepa revenues and we provide no guidance regarding anticipated levels of vascepa revenues . 55 during 2012 , we purchased approximately $ 32 million of vascepa api of which $ 21.3 million was capitalized to inventory as of december 31 , 2012 and the balance of which was included as a component of research and development expense either because it was received prior to fda approval of vascepa for the marine indication or because it was used in conjunction with the reduce-it study . the majority of this supply was purchased in the second half of 2012. we anticipate continuing to make substantial purchases of supply during 2013 and beyond . story_separator_special_tag the decrease in research and development expense was primarily due to decreased costs in 2011 for our vascepa cardiovascular program , primarily costs associated with the marine and anchor trials , our two phase 3 clinical trials , the top-line results of which were reported in december 2010 and april 2011 , respectively . the decrease in costs for these trials in 2011 versus 2010 were partially offset by increased clinical costs for the reduce-it cardiovascular outcomes study , which was initiated in the second half of 2011 , and costs associated with submitting our nda in september 2011 for vascepa . ( 2 ) non-cash stock based compensation expense included within research and development was $ 1.5 million for the years ended december 31 , 2011 and 2010 , respectively . general and administrative expense . general and administrative expense for the year ended december 31 , 2011 was $ 22.6 million , versus $ 17.1 million in the prior year , an increase of $ 5.5 million , or 32.2 % . general and administrative expenses for the years ended december 31 , 2011 and 2010 are summarized in the table below : replace_table_token_9_th ( 1 ) general and administrative expense , excluding restructuring , severance and non-cash compensation charges for stock compensation and warrants , for the year ended december 31 , 2011 was $ 14.8 million , versus $ 7.2 million in the prior year , an increase of $ 7.6 million , or 105.6 % . the increase was primarily due to higher staffing levels in 2011 , increased overhead costs for increased office space and higher costs in 2011 for marketing studies and other pre-commercial activities . ( 2 ) non-cash warrant related compensation ( income ) expense for the year ended december 31 , 2011 was $ 0.1 million of income , versus $ 5.7 million of expense in the prior year , a change of $ 5.8 million . warrant related compensation income for the period ended december 31 , 2011 reflects non-cash income for the change in fair value of the warrant derivative liability associated with warrants issued in october 2009 to three former officers of amarin , net of warrants exercised . the income in 2011 was due primarily to the decrease in the fair value of these warrants , the decrease in the fair value of the warrants is due primarily to a decrease in our stock price between december 31 , 2010 and december 31 , 2011 . ( 3 ) non-cash stock based compensation expense for the year ended december 31 , 2011 was $ 7.8 million , versus $ 3.7 million in the prior year period , an increase of $ 4.1 million due primarily to an increase in option awards granted in late 2010 and during the year ended december 31 , 2011 to attract and retain qualified employees . 60 ( 4 ) restructuring , severance and lease exit costs for the year ended december 31 , 2010 represented costs for severance , office consolidation and the relocation of certain operations to our u.s. offices . ( loss ) gain on change in fair value of derivative liabilities . ( loss ) gain on change in fair value of derivative liability for the year ended december 31 , 2011 was expense of $ 22.7 million versus $ 205.2 million in the prior year period . ( loss ) gain on change in fair value of derivative liability is primarily related to the change in fair value of warrants issued in conjunction with the october 2009 private placement . in october 2009 we issued 36.1 million warrants at an exercise price of $ 1.50 and recorded a $ 48.3 million warrant derivative liability , representing the fair value of the warrants issued . as these warrants have been classified as a derivative liability , they are revalued at each reporting period , with changes in fair value recognized in the statement of operations . the fair value of the warrant derivative liability at december 31 , 2010 was $ 230.1 million and we recognized a $ 205.2 million loss on change in fair value of derivative liability for the period ended december 31 , 2010 for these warrants . the fair value of the warrant derivative liability at december 31 , 2011 was $ 123.1 million and we recognized a $ 22.7 million loss on change in fair value of derivative liability for the period ended december 31 , 2011. the decrease in the warrant derivative liability value was due primarily to the exercises of warrants . upon exercise , the fair value of warrants exercised is remeasured and reclassified from warrant liability to additional paid-in-capital . see further discussion of the warrant derivative liability in note 2 and note 7 of the notes to the consolidated financial statements . interest income ( expense ) , net . interest income includes interest earned on cash balances . interest expense for the year ended december 31 , 2011 was $ 0.001 million versus $ 0.02 million in the prior year . other ( expense ) income , net . other ( expense ) income primarily includes gains and losses on foreign exchange transactions . other ( expense ) income for the year ended december 31 , 2011 was a net expense of $ 0.01 million versus income of $ 0.13 million in the prior year . ( provision for ) benefit from income taxes . provision for the year ending december 31 , 2011 was a $ 2.5 million provision versus a $ 0.5 million benefit in the prior year . the current provision relates entirely to the united states operations . we are profitable in the united states as a result of intercompany transactions between our united states subsidiary and our other companies . the increase in the 2011 provision for income taxes primarily relates to the exercise of stock options of which the excess

